U

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

Territory Business Manager - Rare Disease

Field SalesPosted on Nov 10
Full-timeMassachusetts, USA

About the Job

Requirements

  • A bachelor's degree in a related field is required.
  • A minimum of 4 years of experience in the pharmaceutical, biotech, or medical device industry is required.
  • A minimum of 3 years of sales experience is required.
  • Ability to travel 80% within the assigned territory and 20% for overnight and/or weekend events as needed.
  • A consistent track record of performance is required.
  • Strong written, verbal, and interpersonal skills are required.
  • A valid driver's license is required.

Responsibilities

  • Conduct direct customer-facing interactions and execute brand and sales strategy to demonstrate clinical product value and educate customers on appropriate utilization.
  • Use knowledge of local market trends, institutions, and key customers to maximize results at the territory level.
  • Collaborate with matrix team members to establish and improve territory performance.
  • Partner effectively with internal and external stakeholders.
  • Use internal resources and data analysis to create territory business plans that drive results.
  • Identify opportunities to build organizational efficiency and improve processes.
  • Understand the opportunities unique to the assigned geography.

Desired Qualifications

  • Two or more years of hospital or large-account experience.
  • Two or more years of experience in uro-oncology, oncology, rare disease, or medical devices.
  • Experience with Buy & Bill products.
  • Experience in Urological Rare Disease.

About the Company

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

UroGen Pharma develops RTGel-based drug-delivery therapies for urothelial and specialty cancers, commercializing products like Jelmyto and ZUSDURI and advancing a pipeline that includes UGN-102, UGN-103, UGN-104, and UGN-301. Its RTGel platform is liquid at cool temperatures and gels at body temperature, allowing chemotherapy to stay at the treatment site longer for local, sustained exposure. The company differentiates itself by delivering established chemotherapy directly to the disease site to reduce systemic exposure and by building a multi-product portfolio focused on urothelial cancers. Its goal is to improve local treatment outcomes and grow a diversified, globally commercial portfolio through ongoing clinical development and partnerships.

Company size
201-500
Company stage
IPO
Headquarters
Princeton, NJ
Founded
2004

Recently Posted Jobs

Explore more opportunities at UroGen Pharma, Inc

See more jobs